RE:RE:Between the line...
Yeah I remember some pretty optimistic resin sales projections around this as well. In fairness to Pierre tho, I think most of Wall Street had very high expectations Albiglutide before being ratcheted down about a year ago, so its not a really big surprise. As some of you have pointed out, we just dont have much of a handle on what that really means on a recurring basis.
Its been fairly widely discsussed that GSK has been hyper sensitive about the use of their name being PR'd in conjunction with these PLI resin purposes. We can only assume it has to do with competitive concerns.
My read is this, the renewal and use of their name in the PR is definitely an indicative of a step forward in the relationship. l think PLI has the GSK resin in their 2015 numbers, so one would think some info on an associated order would follow.
WIth the broader drug maker market moving towards plasma derived drugs, I am curious how many other initiatives PLI is engaged with GSK on right now, and where this may lead.
This may be a bit of a fart in a windstorm to the market today with the Hedgie shenanigans and margin calls playing out, but there is likely more to this than on the surface. Although that wouldnt be hard, cuz its a pretty sterile release. Wonder how much the teams of lawyers collectively charged to vet that one between the two companies !! ?
I think we are in the process of putting in a longer term bottom here. Bring on some of the other 4050 stuff they have telegraphed